8-K Announcements
6Material company update
Mar 13, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Jan 23, 2026·SEC
Corvus Pharmaceuticals, Inc.(CRVS)Earnings, Financials & Key Ratios
CRVS•NASDAQ
$15.45
$1.15B mkt cap·Price updated May 6, 2026
AboutCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.Show more
- Revenue$0
- EBITDA-$43M-56.5%
- Net Income-$15M+75.5%
- EPS (Diluted)-0.53+48.0%
- ROE-32.6%+81.4%
- ROIC-78.11%+1.0%
- Debt/Equity0.02-55.6%
- Interest Coverage-17.15
CRVS Key Insights
Corvus Pharmaceuticals, Inc. (CRVS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 93 (top 7%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 30.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 20.1x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CRVS Price & Volume
Corvus Pharmaceuticals, Inc. (CRVS) stock price & volume — 10-year historical chart
Loading chart...
CRVS Growth Metrics
Corvus Pharmaceuticals, Inc. (CRVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM75.47%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM45.36%
Return on Capital
10 Years-54.89%
5 Years-60.25%
3 Years-71.74%
Last Year-90.23%
CRVS Recent Earnings
Corvus Pharmaceuticals, Inc. (CRVS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
Mar 12, 2026EPS
$0.15
Est $0.14
-7.1%
Revenue
—
Est $775,000
Q4 2025
Nov 4, 2025EPS
$0.12
Est $0.14
+14.3%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.10
Est $0.13
+23.1%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.13
Est $0.13
+0.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.15vs $0.14-7.1% | —vs $775,000 |
| Q4 2025 | Nov 4, 2025 | $0.12vs $0.14+14.3% | — |
| Q3 2025 | Aug 7, 2025 | $0.10vs $0.13+23.1% | — |
| Q2 2025 | May 8, 2025 | $0.13vs $0.13+0.0% | — |
Based on last 12 quarters of dataView full earnings history →
CRVS Peer Comparison
Corvus Pharmaceuticals, Inc. (CRVS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TPVG | 225.54M | 5.57 | 4.57 | 36.55% | 13.09% | 1.33 | ||
 NKTX | 234.54M | 3.32 | -2.08 | -30.37% | 0.20 | |||
 ALEC | 283.63M | 2.57 | -1.85 | -79.07% | -6.79% | -466.34% | 1.18 | |
 EXEL | 12.37B | 48.70 | 17.52 | 6.98% | 35.08% | 40.21% | 0.08 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 |
Compare CRVS vs Peers
Corvus Pharmaceuticals, Inc. (CRVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRVS Income Statement
Corvus Pharmaceuticals, Inc. (CRVS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 842K | 847K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -842K▲ 0% | -847K▼ 0.6% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -41.75% | -0.59% | 100% | - | - | - | - | - | - |
| Operating Expenses | 56.52M | 49.22M | 48.85M | 43.76M | 38.63M | 32.56M | 23.41M | 27.55M | 42.97M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 10.22M | 10.64M | 10.88M | 11.93M | 9.52M | 8.1M | 6.88M | 8.16M | 9.25M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 46.3M | 38.59M | 37.98M | 31.83M | 29.11M | 24.47M | 16.53M | 19.39M | 33.72M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -56.52M▲ 0% | -49.22M▲ 12.9% | -48.85M▲ 0.7% | -43.76M▲ 10.4% | -38.63M▲ 11.7% | -32.56M▲ 15.7% | -23.41M▲ 28.1% | -27.55M▼ 17.7% | -42.97M▼ 56.0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -52.87% | 12.92% | 0.75% | 10.43% | 11.72% | 15.7% | 28.12% | -17.69% | -55.99% |
| EBITDA | -55.68M | -48.38M | -48.11M | -43.13M | -38.17M | -32.2M | -23.26M | -27.46M | -42.97M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -53.05% | 13.12% | 0.55% | 10.36% | 11.5% | 15.65% | 27.77% | -18.09% | -56.47% |
| D&A (Non-Cash Add-back) | 842K | 847K | 743K | 632K | 460K | 367K | 151K | 85K | 0 |
| EBIT | -55.66M | -46.94M | -48.85M | -6M | -38.63M | -32.56M | -23.41M | -27.55M | 0 |
| Net Interest Income | 0 | 0 | 0 | 0 | -15K | 654K | 1.58M | 1.82M | 0 |
| Interest Income | 861K | 2.28M | 2.18M | 540K | 0 | 654K | 1.58M | 1.82M | 0 |
| Interest Expense | 0 | 2.28M | 2.18M | 540K | 15K | 0 | 0 | 0 | 2.5M |
| Other Income/Expense | 861K | 2.28M | 2.18M | 37.77M | -4.61M | -8.74M | -3.62M | -34.74M | 27.69M |
| Pretax Income | -55.66M▲ 0% | -46.94M▲ 15.7% | -46.67M▲ 0.6% | -6M▲ 87.2% | -43.24M▼ 621.3% | -41.31M▲ 4.5% | -27.03M▲ 34.6% | -62.29M▼ 130.5% | -15.28M▲ 75.5% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -55.66M▲ 0% | -46.94M▲ 15.7% | -46.67M▲ 0.6% | -6M▲ 87.2% | -43.24M▼ 621.3% | -41.31M▲ 4.5% | -27.03M▲ 34.6% | -62.29M▼ 130.5% | -15.28M▲ 75.5% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -53.03% | 15.67% | 0.57% | 87.16% | -621.28% | 4.47% | 34.57% | -130.47% | 75.47% |
| Net Income (Continuing) | -55.66M | -46.94M | -46.67M | -6M | -43.24M | -41.31M | -27.03M | -62.29M | -15.28M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.72▲ 0% | -1.71▲ 37.1% | -1.49▲ 12.9% | -0.20▲ 86.6% | -1.03▼ 415.0% | -0.89▲ 13.6% | -0.56▲ 36.8% | -1.02▼ 81.2% | -0.53▲ 48.0% |
| EPS Growth % | -15.25% | 37.13% | 12.87% | 86.58% | -415% | 13.59% | 36.76% | -81.24% | 48.04% |
| EPS (Basic) | -2.72 | -1.71 | -1.49 | -0.20 | -1.03 | -0.89 | -0.56 | -1.02 | -0.19 |
| Diluted Shares Outstanding | 20.49M | 27.51M | 29.35M | 29.48M | 41.85M | 46.55M | 48.03M | 60.99M | 79.74M |
| Basic Shares Outstanding | 20.49M | 27.51M | 29.35M | 29.48M | 41.85M | 46.55M | 48.03M | 60.99M | 78.96M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CRVS Balance Sheet
Corvus Pharmaceuticals, Inc. (CRVS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 90.06M | 114.6M | 79.34M | 45.34M | 71.31M | 43.66M | 27.96M | 54.41M | 58.21M |
| Cash & Short-Term Investments | 90.06M | 114.6M | 77.98M | 44.26M | 69.45M | 42.3M | 27.15M | 51.96M | 56.75M |
| Cash Only | 90.06M | 114.6M | 5.15M | 16.45M | 63.46M | 13.16M | 12.62M | 8.74M | 4.58M |
| Short-Term Investments | 0 | 0 | 72.83M | 27.8M | 5.99M | 29.14M | 14.53M | 43.22M | 52.17M |
| Accounts Receivable | 132K | 337K | 329K | 0 | 539K | 633K | 63K | 216K | 37K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | -852K | -602K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 720K | 265K | 486K | 673K | 128K | 102K | 220K | 548K | 1.43M |
| Total Non-Current Assets | 4.72M | 3.63M | 4.3M | 40.19M | 38.14M | 24.58M | 17.6M | 14.5M | 12.9M |
| Property, Plant & Equipment | 2.67M | 2.18M | 3.79M | 2.55M | 3.64M | 2.57M | 1.39M | 1.33M | 1.06M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 37.23M | 34.27M | 21.88M | 16.12M | 12.54M | 0 |
| Other Non-Current Assets | 2.05M | 1.46M | 513K | 414K | 236K | 129K | 89K | 632K | 11.85M |
| Total Assets | 94.78M▲ 0% | 118.23M▲ 24.8% | 83.65M▼ 29.3% | 85.53M▲ 2.3% | 109.45M▲ 28.0% | 68.24M▼ 37.7% | 45.55M▼ 33.2% | 68.91M▲ 51.3% | 71.12M▲ 3.2% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -32.38% | 24.75% | -29.25% | 2.25% | 27.97% | -37.65% | -33.25% | 51.27% | 3.21% |
| Total Current Liabilities | 9.94M | 7.9M | 10.22M | 12.15M | 9.69M | 10.75M | 6.87M | 35.4M | 9.38M |
| Accounts Payable | 3.45M | 2M | 2.45M | 3.47M | 1.56M | 1.98M | 1.52M | 2.58M | 2.49M |
| Days Payables Outstanding | 1.5K | 861 | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 878K | 0 | 0 | 0 | 0 | 0 | 403K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.94M | 4.38M | 5.28M | 180K | 1.97M | 1.27M | 929K | 30.02M | 8.98M |
| Current Ratio | 9.06x | 14.51x | 7.76x | 3.73x | 7.36x | 4.06x | 4.07x | 1.54x | 6.21x |
| Quick Ratio | 9.15x | 14.59x | 7.76x | 3.73x | 7.36x | 4.06x | 4.07x | 1.54x | 6.21x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 971K | 869K | 2.31M | 1.23M | 2.6M | 1.37M | 0 | 937K | 534K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 534K |
| Capital Lease Obligations | 0 | 0 | 2.31M | 1.23M | 2.6M | 1.37M | 0 | 937K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 971K | 869K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 9.94M | 7.9M | 12.54M | 13.38M | 12.29M | 12.13M | 6.87M | 36.34M | 9.91M |
| Total Debt | 0 | 0 | 3.19M | 2.31M | 3.65M | 2.6M | 1.37M | 1.12M | 937K |
| Net Debt | -90.06M | -114.6M | -1.97M | -14.14M | -59.81M | -10.56M | -11.25M | -7.62M | -3.64M |
| Debt / Equity | - | - | 0.04x | 0.03x | 0.04x | 0.05x | 0.04x | 0.03x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -21.56x | -22.39x | -81.04x | -2575.33x | - | - | - | -17.15x |
| Total Equity | 84.83M▲ 0% | 110.34M▲ 30.1% | 71.11M▼ 35.6% | 72.15M▲ 1.5% | 97.16M▲ 34.7% | 56.12M▼ 42.2% | 38.68M▼ 31.1% | 32.57M▼ 15.8% | 61.2M▲ 87.9% |
| Equity Growth % | -36.12% | 30.06% | -35.55% | 1.46% | 34.67% | -42.25% | -31.06% | -15.81% | 87.93% |
| Book Value per Share | 4.14 | 4.01 | 2.42 | 2.45 | 2.32 | 1.21 | 0.81 | 0.53 | 0.77 |
| Total Shareholders' Equity | 84.83M | 110.34M | 71.11M | 72.15M | 97.16M | 56.12M | 38.68M | 32.57M | 61.2M |
| Common Stock | 2K | 3K | 3K | 3K | 5K | 5K | 5K | 7K | 7K |
| Retained Earnings | -123.53M | -170.47M | -217.15M | -223.14M | -266.38M | -307.69M | -334.72M | -397.01M | -412.29M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -41K | -34K | 29K | 4K | 1.87M | -563K | -967K | -1.29M | -896K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRVS Cash Flow Statement
Corvus Pharmaceuticals, Inc. (CRVS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -46.21M | -40.99M | -37.32M | -34.78M | -36.72M | -27.02M | -23.93M | -25.42M | -32.8M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -65.89% | 11.3% | 8.95% | 6.81% | -5.57% | 26.4% | 11.43% | -6.22% | -29% |
| Net Income | -55.66M | -46.94M | -46.67M | -6M | -43.24M | -41.31M | -27.03M | -62.29M | -15.28M |
| Depreciation & Amortization | 842K | 847K | 743K | 632K | 460K | 367K | 151K | 85K | 105K |
| Stock-Based Compensation | 6.23M | 7.13M | 7.35M | 5.75M | 4.23M | 2.69M | 2.15M | 3M | 5.33M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -195K | -608K | -644K | -37.07M | 5.07M | 9.81M | 4.39M | 35.43M | -22.95M |
| Working Capital Changes | 2.58M | -1.42M | 1.9M | 1.91M | -3.24M | 1.41M | -3.59M | -1.65M | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | -507K | -81K | 562K | -49K | 38K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.55M | -1.46M | 450K | 1.02M | -1.9M | 411K | -451K | 1.06M | -91K |
| Cash from Investing | 84.83M | -30.19M | 3.25M | 44.77M | 21.56M | -23.28M | 15.54M | -27.48M | -7.8M |
| Capital Expenditures | -266K | -355K | -25K | -76K | -5K | -269K | -34K | 0 | -174K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | -44.84K | -21.57K | 22K | 0 | 5K | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 85.09M | -29.84M | 0 | 44.84K | 21.57K | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.44M | 65.27M | 24K | 1.31M | 62.16M | 0 | 7.86M | 49.03M | 36.43M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 711K | 1000K | 0 | 1000K | 1000K | 0 | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 731K | 393K | 24K | 88K | 1.22M | 0 | 12K | 32.62M | 36.43M |
| Net Change in Cash | 40.06M▲ 0% | -5.91M▼ 114.8% | -34.04M▼ 476.0% | 11.3M▲ 133.2% | 47M▲ 315.9% | -50.3M▼ 207.0% | -539K▲ 98.9% | -3.88M▼ 619.9% | -4.16M▼ 7.3% |
| Free Cash Flow | -46.48M▲ 0% | -41.34M▲ 11.0% | -37.35M▲ 9.7% | -34.85M▲ 6.7% | -36.72M▼ 5.4% | -27.29M▲ 25.7% | -23.97M▲ 12.2% | -25.42M▼ 6.1% | -32.97M▼ 29.7% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -54.64% | 11.05% | 9.67% | 6.67% | -5.35% | 25.68% | 12.18% | -6.07% | -29.68% |
| FCF per Share | -2.27 | -1.50 | -1.27 | -1.18 | -0.88 | -0.59 | -0.50 | -0.42 | -0.41 |
| FCF Conversion (FCF/Net Income) | 0.83x | 0.87x | 0.80x | 5.80x | 0.85x | 0.65x | 0.89x | 0.41x | 2.15x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRVS Key Ratios
Corvus Pharmaceuticals, Inc. (CRVS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -71.53% | -51.15% | -48.1% | -51.44% | -8.37% | -51.08% | -53.9% | -57.02% | -174.85% | -32.6% |
| Return on Invested Capital (ROIC) | - | - | - | -112.94% | -51.62% | -60.77% | -58.92% | -48.1% | -78.88% | -78.11% |
| Debt / Equity | - | - | - | 0.04x | 0.03x | 0.04x | 0.05x | 0.04x | 0.03x | 0.02x |
| Interest Coverage | -61.52x | - | -21.56x | -22.39x | -81.04x | -2575.33x | - | - | - | -17.15x |
| FCF Conversion | 0.77x | 0.83x | 0.87x | 0.80x | 5.80x | 0.85x | 0.65x | 0.89x | 0.41x | 2.15x |
CRVS SEC Filings & Documents
Corvus Pharmaceuticals, Inc. (CRVS) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRVS Frequently Asked Questions
Corvus Pharmaceuticals, Inc. (CRVS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Corvus Pharmaceuticals, Inc. (CRVS) grew revenue by 0.0% over the past year. Growth has been modest.
Corvus Pharmaceuticals, Inc. (CRVS) reported a net loss of $15.3M for fiscal year 2025.
Dividend & Returns
Corvus Pharmaceuticals, Inc. (CRVS) has a return on equity (ROE) of -32.6%. Negative ROE indicates the company is unprofitable.
Corvus Pharmaceuticals, Inc. (CRVS) had negative free cash flow of $33.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More CRVS
Corvus Pharmaceuticals, Inc. (CRVS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates